DiaSorin (OTCMKTS:DSRLF) Shares Down 1.7% – Here’s Why

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s share price dropped 1.7% during trading on Friday. The company traded as low as $84.00 and last traded at $84.00. 5 shares changed hands during mid-day trading, The stock had previously closed at $85.47.

Analysts Set New Price Targets

A number of research firms have weighed in on DSRLF. Piper Sandler assumed coverage on shares of DiaSorin in a research report on Thursday, June 11th. They set a “neutral” rating for the company. UBS Group cut shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. Zacks Research downgraded shares of DiaSorin from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 6th. BNP Paribas Exane lowered shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of DiaSorin in a research report on Tuesday, August 4th. One analyst has rated the stock with a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Strong Sell”.

DiaSorin Stock Down 1.7%

The stock has a fifty day simple moving average of $84.89 and a two-hundred day simple moving average of $77.57.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italian healthcare company that develops, manufactures and markets in vitro diagnostic products. Its portfolio is focused on immunodiagnostics and molecular diagnostics used to support the detection and monitoring of diseases and medical conditions.

The company offers diagnostic assays, reagents and analytical systems for areas including infectious diseases, endocrinology, oncology, autoimmune disorders, bone and mineral metabolism, cardiovascular conditions and gastrointestinal diseases.